Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States

Jia, X., Zhao, Y., Carrico, J., Brodtkorb, T-H., Mendelsohn, A., Lowry, S., Feldman, S., Wu, JJ., & Armstrong, A. (2018). Cost-effectiveness analysis of tildrakizumab in patients with moderate to severe plaque psoriasis in the United States. Journal of managed care & specialty pharmacy, 24(10-a Suppl), S79. https://doi.org/10.18553/jmcp.2018.24.10-a.s1

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

OCCASIONAL PAPER

Bringing an equity-centered framework to research
OCCASIONAL PAPER

The Preschool Entitlement
OCCASIONAL PAPER

Culturally informed community engagement
Article

Does the relationship between alcohol retail environment and alcohol outcomes vary by depressive symptoms? Findings from a US Survey of Black, Hispanic and White drinkers